HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

COPAC protocol

chemotherapy protocol consisting of above cpds

Also Known As:

PACCO

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - COPAC protocol: 3
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - COPAC protocol: 3
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - COPAC protocol: 3
Inorganic Chemicals: 9
Organic Chemicals: 133
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthacenes
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        COPAC protocol: 3
Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        COPAC protocol: 3
Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Indole Alkaloids: 200
    - Secologanin Tryptamine Alkaloids: 81
      - Vinca Alkaloids: 463
        Vincristine: 9251
        COPAC protocol: 3
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Secologanin Tryptamine Alkaloids: 81
        Vinca Alkaloids: 463
        Vincristine: 9251
        COPAC protocol: 3
    - Indolizines: 3
      - Indolizidines: 2
        Indole Alkaloids: 200
        Secologanin Tryptamine Alkaloids: 81
        Vinca Alkaloids: 463
        Vincristine: 9251
        COPAC protocol: 3

Related Diseases

1.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/01/1985 - "To evaluate the role of cisplatinum in the treatment of advanced non-small cell lung cancer, 48 patients received either a doxorubicin (adriamycin) 50 mg/m2 I.V., cyclophosphamide 300 mg/m2 I.V., lomustine (CCNU) 50 mg/m2 p.o., vincristine (oncovin) 1.2 mg/m2 I.V. (ACCO) combination or the same drugs plus cisplatinum 50 mg/m2 I.V. (PACCO) in a prospective sequential trial. " 07/01/1995 - "Previously, we reported an effective chemotherapeutic combination regimen for non-small cell lung carcinoma (NSCLC): cisplatinum, doxorubicin, cyclophosphamide, CCNU, and vincristine (PACCO). "
2.	Vomiting 04/01/1985 - "Predominant toxicity consisted of moderately severe nausea and vomiting (63% on PACCO vs. 34% on ACCO, p less than 0.05) and myelosuppression with WBC less than 3,000/mm3 occurring in the majority of patients on both regimens. "
3.	Nausea 04/01/1985 - "Predominant toxicity consisted of moderately severe nausea and vomiting (63% on PACCO vs. 34% on ACCO, p less than 0.05) and myelosuppression with WBC less than 3,000/mm3 occurring in the majority of patients on both regimens. "
4.	Bronchogenic Carcinoma 05/01/1984 - "Cisplatin, doxorubicin, cyclophosphamide, lomustine, and vincristine (PACCO) in the treatment of non-small cell bronchogenic carcinoma."
5.	Carcinoma (Carcinomatosis) 07/01/1995 - "Neoadjuvant chemotherapy of stage III-A and B lung carcinoma using the PACCO regimen."

Related Drugs and Biologics

1.	Vincristine (Oncovin)
2.	Lomustine (CCNU)
3.	Doxorubicin (Adriamycin)
4.	Cyclophosphamide (Cytoxan)
5.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Neoadjuvant Therapy